VOTIS develops a non-invasive medical device that utilizes laser diodes and photodetector sensors to screen, stage, and monitor diabetic foot syndrome and related conditions. This technology provides objective, repeatable data on blood flow and ulcer severity, addressing the critical need for effective management of peripheral artery disease and preventing complications such as amputations.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI) affect millions worldwide, often leading to diabetic foot syndrome and, ultimately, amputations due to hindered blood flow and undetected or poorly managed complications. Current methods for assessing blood flow and ulcer severity in the diabetic foot may lack objectivity and repeatability. Effective tools are needed to aid in the diagnosis, staging, and monitoring of these conditions to prevent severe outcomes.
Solution
VOTIS provides a clinical decision support tool for the diagnosis and monitoring of diabetic foot syndrome and related conditions. The VOTIS system utilizes laser diodes and photodetector sensors in single-use patches affixed to the foot to non-invasively measure light scattering and absorption, providing objective data on blood flow and ulcer characteristics. This data is transmitted digitally and automatically converted into a Wound, Ischemia, Foot Infection (WIFI) scale score, aiding in clinical decision-making throughout the patient journey, from screening to intraoperative assessment. The system is designed for safe, repeated use and aims to provide clinicians with measurable data, regardless of treatment options being used, to improve patient outcomes and reduce amputations. The VOTIS system includes PedCheck for screening, PedStage for assessing blood flow and ulcer severity, and PedFlo for real-time intraoperative blood flow assessment.
Target Audience
The primary target audience includes specialists treating patients with PAD/CLTI and diabetic foot syndrome, including vascular surgeons, interventional cardiologists, and podiatrists, as well as clinical investigators involved in PAD research.
Features
- Non-invasive assessment of blood flow in the foot using laser diodes and photodetector sensors
- Single-use consumable patches for safe and repeated measurements
- Objective, repeatable data to aid in the diagnosis and monitoring of diabetic foot syndrome
- Automated conversion of measurement data into a 3-digit WIFI scale score
- PedFlo provides real-time blood flow assessment during surgical procedures
- Cloud-based data transmission and analysis
- Angiosome mapping to identify areas of the foot lacking perfusion